Abnormal metabolic network activity in Parkinson's disease: test-retest reproducibility.

Abnormal metabolic network activity in Parkinson's disease: test-retest reproducibility. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Abnormal metabolic network activity in Parkinson's disease: test-retest reproducibility. Abstract Text:

Yilong Ma,Chengke Tang,Phoebe G Spetsieris,Vijay Dhawan,David Eidelberg,

Parkinson's disease (PD) is associated with an abnormal pattern of regional brain function. The expression of this PD-related covariance pattern (PDRP) has been used to assess disease progression and the response to treatment. In this study, we validated the PDRP network as a measure of parkinsonism by prospectively computing its expression (PDRP scores) in (15)O-water (H(2)(15)O) and (18)F-fluorodeoxyglucose (FDG) positron emission tomography (PET) scans from PD patients and healthy volunteers. The reliability of this measure was also assessed within subjects using a test-retest design in mildly affected and advanced PD patients scanned at baseline and during treatment with levodopa or deep brain stimulation (DBS). We found that PDRP expression was significantly elevated in PD patients (P<0.001) relative to controls in a prospective analysis of brain scans obtained with either H(2)(15)O or FDG PET. A significant correlation (R(2)=0.61; P<0.001) was evident between PDRP scores computed from H(2)(15)O and FDG images in PD subjects scanned with both tracers. Test-retest reproducibility was very high (intraclass correlation coefficient (ICC)>0.92) for PDRP scores measured both within PET session and between sessions separated by up to 2 months. This high reproducibility was observed in both early stage and advanced PD patients scanned at baseline and during treatment. The within-subject variability of this measure was less than 10% for both unmedicated and treated conditions. These findings suggest that the PDRP network is a reproducible and stable descriptor of regional functional abnormalities in parkinsonism. The quantification of PDRP expression in PD patients can serve as a potential biomarker in PET intervention studies for this disorder.

Abnormal metabolic network activity in Parkinson's disease: test-retest reproducibility. Publishing Authors By Initials

Y Ma,C Tang,PG Spetsieris,V Dhawan,D Eidelberg,

For similar information science: computing methodologies: software research abstracts see: information science: computing methodologies: software research

PUBMED ID PMID:

MEDLINE DATE:

Abnormal metabolic network activity in Parkinson's disease: test-retest reproducibility. Journal Published:

PUBLICATION TYPE: Research Support, N.I.H., Extr

Journal: Journal of cerebral blood flow and metabolism : of

VOLUME: 27

Page Numbers: 597-605

Journal Abbreviation: J. Cereb. Blood Flow Metab.

ISSN: 0271-678X

DAY: 28

MONTH: 06

YEAR: 2006

Abnormal metabolic network activity in Parkinson's disease: test-retest reproducibility. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 8112566

Abnormal metabolic network activity in Parkinson's disease: test-retest reproducibility. Keywords Mesh Terms:

KEYWORDS: Software

MESH TERMS: therapy

Chemical & Substance for Abstract: Abnormal metabolic network activity in Parkinson's disease: test-retest reproducibility. Information

Substance Name: Glucose

Registry Number: 50-99-7

Grant and Affiliation Information for Abnormal metabolic network activity in Parkinson's disease: test-retest reproducibility.

AFFILIATION: Center for Neurosciences, Feinstein Institute for Medical Research, North Shore-Long Island Jewish Health System, Manhasset, NY 11030, USA. yma@nshs.edu

Country: United States

AGENCY: United States NINDS

GRANT: R01 NS 35069

ACRONYM: NS

MEDLINETA: J Cereb Blood Flow Metab

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Abnormal metabolic network activity in Parkinson's disease: test-retest reproducibility Related Publications

• Abnormal metabolic network activity in Parkinson's disease: test-retest reproducibility.
• Abnormal metabolic networks in atypical parkinsonism.
• An examination of executive dysfunction associated with frontostriatal circuitry in Parkinson's disease.
• Callosal and non-callosal connexions between the sensory-motor cortices in cat and monkey.
• Cerebral glucose metabolism and D(2)/D (3) receptor availability in young adults with cannabis dependence measured with positron emission tomography.
• Changes in network activity with the progression of Parkinson's disease.
• Correlates of movement initiation and velocity in Parkinson's disease: A longitudinal PET study.
• Development of electrical activity in the cerebral cortex of the newborn rat.
• Dissociation of metabolic and neurovascular responses to levodopa in the treatment of Parkinson's disease.
• Dopaminergic suppression of brain deactivation responses during sequence learning.
• Functional imaging of cerebral blood flow and glucose metabolism in Parkinson's disease and Huntington's disease.
• Functional imaging of sequence learning in Parkinson's disease.
• Gene transfer therapy for neurodegenerative disorders.
• Habituation of somatosensory evoked potentials in the lemniscal system of the cat.
• Implicit and explicit aspects of sequence learning in pre-symptomatic Huntington's disease.
• Increased cerebellar activation during sequence learning in DYT1 carriers: an equiperformance study.
• Metabolic abnormalities associated with mild cognitive impairment in Parkinson disease.
• Metabolic brain networks associated with cognitive function in Parkinson's disease.
• Metabolic correlates of subthalamic nucleus activity in Parkinson's disease.
• Microstructural white matter changes in primary torsion dystonia.
• Modulation of metabolic brain networks after subthalamic gene therapy for Parkinson's disease.
• Relationship between self-reported apathy and executive dysfunction in nondemented patients with Parkinson disease.
• Spectrum analysis of residual EEG changes following post-natal x-irradiation in rats.
• Subthalamic glutamic acid decarboxylase gene therapy: changes in motor function and cortical metabolism.
• Thalamic metabolism and symptom onset in preclinical Huntington's disease.
• The assessment of neurological systems with functional imaging.
• Thermoelectric freezing stage for serial brain sectioning.
• [Not Available.]
• [Not Available.]
• [Treatment of pain in neoplastic diseases.]